Abstract | BACKGROUND:
Neuromyelitis optica spectrum disorders (NMOSD) is an autoimmune astrocyte disease that mainly affects the optic nerve and spinal cord resulting in blindness or paralysis. Rituximab (RTX) is a chimeric monoclonal antibody directed against the surface antigen of CD20 on B lymphocytes and is an emerging treatment option in NMOSD. The present review aimed to conduct an update systematic review and meta-analysis for the efficacy of RTX in the treatment of NMOSD and analyze main factors affecting the efficacy of RTX. METHODS: The following Medical Subject Heading (MeSH) and related entry terms are used to search English literature in PubMed, MEDLINE and CENTRAL databases, respectively. MeSH include: Neuromyelitis optic and Rituximab; entry terms include: NMO Spectrum Disorder, NMO Spectrum Disorders, Neuromyelitis Optica ( NMO) Spectrum Disorder, Neuromyelitis Optica Spectrum Disorders, Devic Neuromyelitis Optica, Neuromyelitis Optica, Devic, Devic's Disease, Devic Syndrome, Devic's Neuromyelitis Optica, Neuromyelitis Optica ( NMO) Spectrum Disorders, CD20 Antibody, Rituximab CD20 Antibody, Mabthera, IDEC-C2B8 Antibody, GP2013, Rituxan; (note: literature retrieval operators "AND" "OR" "NOT" are used to link MeSH with Entry Terms.) 54 studies were included in this systematic review and 29 studies were included in meta-analysis. The main efficacy indicators were the difference of the expanded disability status scale (EDSS) and annualized relapse rate (ARR) between before and after rituximab treatments. RESULTS: In 29 studies involving 732 patients (643 women, 84 men, 5 with unknown gender), the EDSS and ARR were reduced by an average of -0.57 (95%CI, -0.69 to -0.44), -1.57 (95%CI, -1.78 to -1.35), respectively. CONCLUSION: Our systematic review and update meta-analysis provide new evidences that RTX can effectively improve disability and reduce ARR ratio.
|
Authors | Yupeng Wang, Haoxiao Chang, Xinghu Zhang, Linlin Yin |
Journal | Multiple sclerosis and related disorders
(Mult Scler Relat Disord)
Vol. 50
Pg. 102843
(May 2021)
ISSN: 2211-0356 [Electronic] Netherlands |
PMID | 33609924
(Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
|
Copyright | Copyright © 2021 Elsevier B.V. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal
- Rituximab
|
Topics |
- Antibodies, Monoclonal
- B-Lymphocytes
- Female
- Humans
- Male
- Neuromyelitis Optica
(drug therapy)
- Optic Nerve
- Rituximab
(therapeutic use)
|